![Klaus Dembowsky](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Klaus Dembowsky
Amministratore Delegato presso amcure GmbH
Posizioni attive di Klaus Dembowsky
Società | Posizione | Inizio | Fine |
---|---|---|---|
amcure GmbH
![]() amcure GmbH BiotechnologyHealth Technology amcure GmbH develops active ingredients for the treatment of angiogenesis-related diseases. It offers a peptide based substance, that targets the tumor specific co-receptors. The company was founded by Matthias Klaften and Alexandra Matzke on December 14, 2011 and is headquartered in Eggenstein-Leopoldshafen, Germany. | Amministratore Delegato | - | - |
Storia della carriera di Klaus Dembowsky
Precedenti posizioni note di Klaus Dembowsky
Società | Posizione | Inizio | Fine |
---|---|---|---|
SPEXIS AG | Direttore Tecnico/Scientifico/R&S | 04/10/2012 | - |
Corporate Officer/Principal | 17/11/2009 | 04/10/2012 | |
BAYER AG | Corporate Officer/Principal | - | - |
Ingenium Pharmaceuticals GmbH
![]() Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Corporate Officer/Principal | - | - |
Speedel Pharma AG
![]() Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Amministratore Delegato | - | - |
Formazione di Klaus Dembowsky
Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Statistiche
Distribuzione geografica
Germania | 5 |
Svizzera | 3 |
Posizioni
Corporate Officer/Principal | 3 |
Chief Executive Officer | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Settori
Health Technology | 5 |
Commercial Services | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
BAYER AG | Health Technology |
SPEXIS AG | Health Technology |
Aziende private | 3 |
---|---|
Speedel Pharma AG
![]() Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Health Technology |
Ingenium Pharmaceuticals GmbH
![]() Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Commercial Services |
amcure GmbH
![]() amcure GmbH BiotechnologyHealth Technology amcure GmbH develops active ingredients for the treatment of angiogenesis-related diseases. It offers a peptide based substance, that targets the tumor specific co-receptors. The company was founded by Matthias Klaften and Alexandra Matzke on December 14, 2011 and is headquartered in Eggenstein-Leopoldshafen, Germany. | Health Technology |
- Borsa valori
- Insiders
- Klaus Dembowsky
- Esperienza